Lipid-lowering effect of berberine in human subjects and rats

Yueshan Hu, Erik A. Ehli, Julie Kittelsrud, Patrick J. Ronan, Karen Munger, Terry Downey, Krista Bohlen, Leah Callahan, Vicki Munson, Mike Jahnke, Lindsey L. Marshall, Kelly Nelson, Patricia Huizenga, Ryan Hansen, Timothy J. Soundy, Gareth E. Davies

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Due to serious adverse effects and the limited effectiveness of currently available pharmacological therapies for obesity, many research efforts have focused on the development of drugs from natural products. Our previous studies demonstrated that berberine, an alkaloid originally isolated from traditional Chinese herbs, prevented fat accumulation in vitro and in vivo. In this pilot study, obese human subjects (Caucasian) were given 500 mg berberine orally three times a day for twelve weeks. The efficacy and safety of berberine treatment was determined by measurements of body weight, comprehensive metabolic panel, blood lipid and hormone levels, expression levels of inflammatory factors, complete blood count, and electrocardiograph. A Sprague-Dawley rat experiment was also performed to identify the anti-obesity effects of berberine treatment. The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects. But more interestingly, the treatment significantly reduced blood lipid levels (23% decrease of triglyceride and 12.2% decrease of cholesterol levels) in human subjects. The lipid-lowering effect of berberine treatment has also been replicated in the rat experiment (34.7% decrease of triglyceride and 9% decrease of cholesterol level). Cortisol, calcitriol, ACTH, TSH, FT4, and SHBG levels were not significantly changed following 12 weeks of berberine treatment. However, there was interestingly, an increase in calcitriol levels seen in all human subjects following berberine treatment (mean 59.5% increase, p = 0.11). Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine. Tests of hematological, cardiovascular, liver, and kidney function following berberine treatment showed no detrimental side effects to this natural compound. Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention.

Original languageEnglish (US)
Pages (from-to)861-867
Number of pages7
JournalPhytomedicine
Volume19
Issue number10
DOIs
StatePublished - Jul 15 2012
Externally publishedYes

Fingerprint

Berberine
Lipids
Calcitriol
Weight Loss
Berberine Alkaloids
Triglycerides
Obesity
Cholesterol
Blood Cell Count
Blood Sedimentation
Hematologic Tests
Biological Products
Adrenocorticotropic Hormone
Osteoporosis
Sprague Dawley Rats
Hydrocortisone
Interleukin-6
Electrocardiography
Fats
Body Weight

Keywords

  • Berberine
  • Human
  • Hyperlipidemia
  • Obesity
  • Osteoporosis
  • Pilot study
  • Rat

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

Hu, Y., Ehli, E. A., Kittelsrud, J., Ronan, P. J., Munger, K., Downey, T., ... Davies, G. E. (2012). Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine, 19(10), 861-867. https://doi.org/10.1016/j.phymed.2012.05.009

Lipid-lowering effect of berberine in human subjects and rats. / Hu, Yueshan; Ehli, Erik A.; Kittelsrud, Julie; Ronan, Patrick J.; Munger, Karen; Downey, Terry; Bohlen, Krista; Callahan, Leah; Munson, Vicki; Jahnke, Mike; Marshall, Lindsey L.; Nelson, Kelly; Huizenga, Patricia; Hansen, Ryan; Soundy, Timothy J.; Davies, Gareth E.

In: Phytomedicine, Vol. 19, No. 10, 15.07.2012, p. 861-867.

Research output: Contribution to journalArticle

Hu, Y, Ehli, EA, Kittelsrud, J, Ronan, PJ, Munger, K, Downey, T, Bohlen, K, Callahan, L, Munson, V, Jahnke, M, Marshall, LL, Nelson, K, Huizenga, P, Hansen, R, Soundy, TJ & Davies, GE 2012, 'Lipid-lowering effect of berberine in human subjects and rats', Phytomedicine, vol. 19, no. 10, pp. 861-867. https://doi.org/10.1016/j.phymed.2012.05.009
Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012 Jul 15;19(10):861-867. https://doi.org/10.1016/j.phymed.2012.05.009
Hu, Yueshan ; Ehli, Erik A. ; Kittelsrud, Julie ; Ronan, Patrick J. ; Munger, Karen ; Downey, Terry ; Bohlen, Krista ; Callahan, Leah ; Munson, Vicki ; Jahnke, Mike ; Marshall, Lindsey L. ; Nelson, Kelly ; Huizenga, Patricia ; Hansen, Ryan ; Soundy, Timothy J. ; Davies, Gareth E. / Lipid-lowering effect of berberine in human subjects and rats. In: Phytomedicine. 2012 ; Vol. 19, No. 10. pp. 861-867.
@article{a5e8a8cf303c41b3801c6200548818f2,
title = "Lipid-lowering effect of berberine in human subjects and rats",
abstract = "Due to serious adverse effects and the limited effectiveness of currently available pharmacological therapies for obesity, many research efforts have focused on the development of drugs from natural products. Our previous studies demonstrated that berberine, an alkaloid originally isolated from traditional Chinese herbs, prevented fat accumulation in vitro and in vivo. In this pilot study, obese human subjects (Caucasian) were given 500 mg berberine orally three times a day for twelve weeks. The efficacy and safety of berberine treatment was determined by measurements of body weight, comprehensive metabolic panel, blood lipid and hormone levels, expression levels of inflammatory factors, complete blood count, and electrocardiograph. A Sprague-Dawley rat experiment was also performed to identify the anti-obesity effects of berberine treatment. The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects. But more interestingly, the treatment significantly reduced blood lipid levels (23{\%} decrease of triglyceride and 12.2{\%} decrease of cholesterol levels) in human subjects. The lipid-lowering effect of berberine treatment has also been replicated in the rat experiment (34.7{\%} decrease of triglyceride and 9{\%} decrease of cholesterol level). Cortisol, calcitriol, ACTH, TSH, FT4, and SHBG levels were not significantly changed following 12 weeks of berberine treatment. However, there was interestingly, an increase in calcitriol levels seen in all human subjects following berberine treatment (mean 59.5{\%} increase, p = 0.11). Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine. Tests of hematological, cardiovascular, liver, and kidney function following berberine treatment showed no detrimental side effects to this natural compound. Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention.",
keywords = "Berberine, Human, Hyperlipidemia, Obesity, Osteoporosis, Pilot study, Rat",
author = "Yueshan Hu and Ehli, {Erik A.} and Julie Kittelsrud and Ronan, {Patrick J.} and Karen Munger and Terry Downey and Krista Bohlen and Leah Callahan and Vicki Munson and Mike Jahnke and Marshall, {Lindsey L.} and Kelly Nelson and Patricia Huizenga and Ryan Hansen and Soundy, {Timothy J.} and Davies, {Gareth E.}",
year = "2012",
month = "7",
day = "15",
doi = "10.1016/j.phymed.2012.05.009",
language = "English (US)",
volume = "19",
pages = "861--867",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",
number = "10",

}

TY - JOUR

T1 - Lipid-lowering effect of berberine in human subjects and rats

AU - Hu, Yueshan

AU - Ehli, Erik A.

AU - Kittelsrud, Julie

AU - Ronan, Patrick J.

AU - Munger, Karen

AU - Downey, Terry

AU - Bohlen, Krista

AU - Callahan, Leah

AU - Munson, Vicki

AU - Jahnke, Mike

AU - Marshall, Lindsey L.

AU - Nelson, Kelly

AU - Huizenga, Patricia

AU - Hansen, Ryan

AU - Soundy, Timothy J.

AU - Davies, Gareth E.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Due to serious adverse effects and the limited effectiveness of currently available pharmacological therapies for obesity, many research efforts have focused on the development of drugs from natural products. Our previous studies demonstrated that berberine, an alkaloid originally isolated from traditional Chinese herbs, prevented fat accumulation in vitro and in vivo. In this pilot study, obese human subjects (Caucasian) were given 500 mg berberine orally three times a day for twelve weeks. The efficacy and safety of berberine treatment was determined by measurements of body weight, comprehensive metabolic panel, blood lipid and hormone levels, expression levels of inflammatory factors, complete blood count, and electrocardiograph. A Sprague-Dawley rat experiment was also performed to identify the anti-obesity effects of berberine treatment. The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects. But more interestingly, the treatment significantly reduced blood lipid levels (23% decrease of triglyceride and 12.2% decrease of cholesterol levels) in human subjects. The lipid-lowering effect of berberine treatment has also been replicated in the rat experiment (34.7% decrease of triglyceride and 9% decrease of cholesterol level). Cortisol, calcitriol, ACTH, TSH, FT4, and SHBG levels were not significantly changed following 12 weeks of berberine treatment. However, there was interestingly, an increase in calcitriol levels seen in all human subjects following berberine treatment (mean 59.5% increase, p = 0.11). Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine. Tests of hematological, cardiovascular, liver, and kidney function following berberine treatment showed no detrimental side effects to this natural compound. Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention.

AB - Due to serious adverse effects and the limited effectiveness of currently available pharmacological therapies for obesity, many research efforts have focused on the development of drugs from natural products. Our previous studies demonstrated that berberine, an alkaloid originally isolated from traditional Chinese herbs, prevented fat accumulation in vitro and in vivo. In this pilot study, obese human subjects (Caucasian) were given 500 mg berberine orally three times a day for twelve weeks. The efficacy and safety of berberine treatment was determined by measurements of body weight, comprehensive metabolic panel, blood lipid and hormone levels, expression levels of inflammatory factors, complete blood count, and electrocardiograph. A Sprague-Dawley rat experiment was also performed to identify the anti-obesity effects of berberine treatment. The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects. But more interestingly, the treatment significantly reduced blood lipid levels (23% decrease of triglyceride and 12.2% decrease of cholesterol levels) in human subjects. The lipid-lowering effect of berberine treatment has also been replicated in the rat experiment (34.7% decrease of triglyceride and 9% decrease of cholesterol level). Cortisol, calcitriol, ACTH, TSH, FT4, and SHBG levels were not significantly changed following 12 weeks of berberine treatment. However, there was interestingly, an increase in calcitriol levels seen in all human subjects following berberine treatment (mean 59.5% increase, p = 0.11). Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine. Tests of hematological, cardiovascular, liver, and kidney function following berberine treatment showed no detrimental side effects to this natural compound. Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention.

KW - Berberine

KW - Human

KW - Hyperlipidemia

KW - Obesity

KW - Osteoporosis

KW - Pilot study

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=84864396863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864396863&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2012.05.009

DO - 10.1016/j.phymed.2012.05.009

M3 - Article

C2 - 22739410

AN - SCOPUS:84864396863

VL - 19

SP - 861

EP - 867

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

IS - 10

ER -